Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 22, 2021

Predictors of Poor Seroconversion and Adverse Events Associated With the COVID-19 mRNA BNT162b2 Vaccine in Cancer Patients on Active Treatment

European Journal of Cancer


Additional Info

European Journal of Cancer
Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment
Eur. J. Cancer 2021 Oct 10;[EPub Ahead of Print], TB Webber, N Provinciali, M Musso, et al

Further Reading